FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1759-1760 June 16, 1994 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Como, J. A. PubMed Citation

To the Editor: The review of oral azole drugs for systemic antifungal therapy, by Como and Dismukes (Jan. 27 issue),¹ was informative but lacked a discussion of the use of these agents in children. Clinicians who treat children have long been seeking an alternative to amphotericin B and have started using azole agents despite the lack of data on the pharmacokinetics, safety, and efficacy of these drugs in children. Ketoconazole is the azole most familiar to clinicians caring for children and is currently the only oral agent for which there is an established dose for children (5 to 10 mg . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.